MEDICA, the world’s largest and most influential trade fair for medical products, technologies and services, serves as the industry’s innovation compass and the premier showcase for companies to unveil breakthroughs and forge global partnerships. This year Micropoint Biotechnologies returned to the arena, competing with top-tier brands and capturing the spotlight with internationally competitive solutions that commanded attention from specialists worldwide.
As a company deeply rooted in the field of rapid diagnostic testing and continuously expanding the international market presence, Micropoint Biotechnologies showcased its two core product series at this exhibition, covering two key scenarios: emergency and critical care, and flexible coagulation testing.
mLabs® Microfluidic Fluorescence Immunoassay Platform – Bedside Power for ER & ICU
The mLabs® platform focuses on chest pain centers and emergency critical care scenarios, and its testing items cover key indicators such as Troponin I, TnI/CK-MB/Myo myocardial infarction triple markers, BNP/NT-proBNP heart failure screening and monitoring, and PCT sepsis detection. The mLabs platform demonstrates excellent performance in whole blood testing speed, sensitivity, anti-interference ability, and dry chemistry reagent stability, directly competing with mainstream international POCT brands. It has been widely used in the emergency and critical care units of many top-tier hospitals in developingcountries and has received high recognition from clinical users.
qLabs® Electrochemistry Coagulation Platform- Handheld POC Coagulation Monitoring at Anytime.
The qLabs® series supports coagulation testing in various flexible scenarios, covering home monitoring ofPT-INR for warfarin-anticoagulated patients (such as those with atrial fibrillation, post-mechanical valve surgery, artificial heart patients, and those at risk of venous thrombosis), professional testing by family doctors and community physicians, and PT/APTT coagulation factor screening for emergency patients, as well as post-operative APTT monitoring for standard heparin. The qLabs platform has been widely installed and used in Europe. Furthermore, the qLabs veterinary coagulation testing platform has also gained widespread application and customer recognition in North America and Western Europe due to its excellent performance and distinctive testing features.
During the exhibition, Micropoint Biotechnologies booth attracted numerous international professional visitors, and on-site exchanges were enthusiastic. Our team conducted multiple rounds of in-depth discussions with global customers regarding product performance and application scenarios, and the technological advancement and clinical applicability of the products were widely recognized. At the same time, our team also had in-depth discussions with new and existing customers from various countries on future market opportunities and growth paths, laying a solid foundation for accelerating global market expansion and deepening regional cooperation.
We will continue to focus on the research and development of core technologies in the field of rapid diagnostics, continuously iterating its product portfolio and optimizing its service system, aiming to become aleading global supplier of chronic disease diagnostic solutions. In the future, we will contribute to the innovative development of the global healthcare industry with more mature technologies, higher-quality products, and superior services, and looks forward to collaborating with global partners again at the next MEDICA exhibition to explore new opportunities for industry development.